Literature DB >> 1712349

Hemipelvectomy in malignant neoplasms of the hip region.

R Capanna1, M Manfrini, G Pignatti, C Martelli, G Gamberini, M Campanacci.   

Abstract

The authors report the results of 76 hemipelvectomies performed from 1978 to 1988 in malignant neoplasms of the hip region. Several surgical techniques were employed, including King and Steelquist's "classic" technique (77%), the technique involving the anterior flap of the thigh (9%), and the technique involving the subcutaneous gluteal flap (14%). In 8 cases palliative surgery was performed. Of the remaining 68 patients, 31 (45%) are alive and show no signs of the disease after an average of 44 months. Postoperative complications are discussed in relation to surgical technique and previous adjuvant therapy; the subcutaneous gluteal flap technique exposes the patient to the greatest risk of major complications (54%), while the "classic" technique is the most reliable, although there was superficial infection in 18% of cases. Fifty percent of the patients previously treated with radiotherapy suffered local postoperative complications. In order to reduce local recurrence, special care is advised in the preoperative stages and in the execution of the pelvic osteotomies.

Entities:  

Mesh:

Year:  1990        PMID: 1712349

Source DB:  PubMed          Journal:  Ital J Orthop Traumatol        ISSN: 0390-5489


  3 in total

1.  Periacetabular reconstruction with a new endoprosthesis.

Authors:  Lawrence R Menendez; Elke R Ahlmann; Yuri Falkinstein; Daniel C Allison
Journal:  Clin Orthop Relat Res       Date:  2009-08-20       Impact factor: 4.176

2.  Complications and outcome of external hemipelvectomy in the management of pelvic tumors.

Authors:  J P Apffelstaedt; D L Driscoll; J E Spellman; A F Velez; J F Gibbs; C P Karakousis
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

3.  [Ablative procedures in surgical treatment of malignant bone tumors].

Authors:  P-U Tunn; H Delbrück; P M Schlag
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.